MSK-IMPACT Analysis of 52,236 Patients Links Cachexia Episodes to Tumor Mutations and Recurring Blood-Test Patterns

Researchers examined longitudinal BMI trajectories, 2 million weight records, serial labs, and tumor genomics in 52,236 patients. Cachexia manifested as discrete wasting episodes rather than steady decline, with 60 percent of events coinciding within 90 days of documented disease progression on imaging. Blood-test signatures including declining albumin and rising CRP tracked these episodes consistently across tumor lineages, extending far beyond gastrointestinal malignancies traditionally associated with the syndrome.

The study design leveraged existing clinical streams rather than prospective cachexia-specific collection, allowing detection of mutation-level associations such as KRAS and TP53 alterations enriched in patients experiencing multiple wasting cycles. This observational approach cannot establish causality but identifies mechanistic leads for interventional trials targeting metabolic pathways downstream of these mutations.

Integration with prior smaller cohorts from Janowitz and Fearon groups strengthens the finding that cachexia is biologically driven and temporally linked to tumor dynamics. The absence of approved therapies makes these routine-data biomarkers immediately actionable for risk stratification in ongoing supportive-care studies.

Next steps require prospective validation cohorts with standardized cachexia endpoints and randomized testing of early nutritional or anti-inflammatory interventions triggered by the identified blood signatures.